长寿科技正成为全球资本的新宠。《2024年度长寿投资报告》显示，过去一年全球长寿领域融资额高达84.9亿美 （数据涵盖1415家长寿产业公司、35,392家生物科技公司和48,825家金融科技公司） 2025年9月，在瑞士格施塔德召开的"长寿投资者大会"（Longevity Investors Conference）上，一位基金合伙人 直言："我们不再追逐'永生幻想'，而是寻找能真正改变人体机能的科学突破。" 资本走向理性，押注"可落地"的抗衰科技 投资Altos Labs以"细胞重编程"探索重返青春的可能。 元，较前一年翻倍增长。投资人从"不死神话"回归理性，开始只投能12至24个月内交付临床成果的项目。 图注：2024年度长寿投资报告一览表 近几年，科技富豪们投资的风向已悄然发生了改变，大健康产业成为了"香馍馍"。硅谷科技富豪布莱恩·约翰逊每 年投入200万美元维持自己的Project Blueprint体系，严格控制卡路里摄入、监测每个睡眠周期；"ChatGPT之 父"山姆·奥特曼出资13亿元押注Retro Biosciences，尝试通过"自噬重启"药物延长健康寿命；亚马逊掌陀人贝佐斯 图注：Long ...

Core Insights - The Chinese cell reprogramming industry is rapidly developing and is becoming a significant force in the global cell reprogramming field, with a projected market size of approximately 857 million yuan in 2024, representing a year-on-year growth of 37.78% [1][7] - A breakthrough by Deng Hongkui's team in 2025 will reduce the time required to induce somatic cells into pluripotent stem cells from 30 days to 10 days, while increasing the induction efficiency by 20 times, enhancing the efficiency, quality, and cost-effectiveness of cell preparation for clinical applications [1][7] Industry Overview - Cell reprogramming involves altering gene expression patterns without changing the genetic sequence through epigenetic modifications, transcription factor regulation, or chemical interventions, allowing cells to revert to a pluripotent state [2] - The industry has evolved through three main stages: exploration, breakthrough, and transformation, starting from the 1950s with nuclear transfer research and leading to significant advancements in the 21st century, including the discovery of the OSKM factors and the development of chemical reprogramming techniques [3] Market Size - The Chinese cell reprogramming market is expected to reach approximately 857 million yuan in 2024, with a growth rate of 37.78% compared to the previous year [7][8] Key Companies - Notable companies in the industry include Zhongyuan Xiehe (600645), Nanhua Biological (000504), and Heyuan Biotechnology (688238), among others, which are actively involved in the development and application of cell reprogramming technologies [2][8] Industry Development Trends 1. **Technological Breakthroughs and Clinical Applications**: The rapid chemical reprogramming system developed by Deng Hongkui's team is expected to significantly enhance the development of clinical-grade products such as pancreatic and cardiac cells [10] 2. **Policy Framework and Regulation**: The establishment of a comprehensive policy framework by the national government aims to standardize research and clinical practices, with pilot policies in regions like Hainan and Shenzhen facilitating advanced cell therapy technologies [11][12] 3. **Industry Chain Integration and International Cooperation**: The industry is witnessing increased collaboration across the supply chain, with domestic companies enhancing the localization of key technologies and international partnerships fostering product development and technological exchange [13]

人体由约30万亿个细胞构成，每个细胞每秒发生近10亿次化学反应。一分钟内的生命活动规模如此庞 大，以至于"百亿亿次"这样的数值也仅能描述其冰山一角。 近年来，科学家不断深入探索细胞内部，从细胞核到基因组，逐步揭示微观世界的复杂性。他们发现， 大多数人类疾病并非单一因素导致，而是源于错综复杂的生物网络共同作用。面对浩瀚的生命数据，传 统方法难以应对。如今，人工智能（AI）正成为破解这一难题的关键。 读懂"生命语法" AI正以一种突破性的视角重新解读生物学：它将蛋白质序列视为一种可被解译的语言。 加速科学发现 Wake和Dyno的AI模型用于非常具体的任务，而非营利研究机构"未来之屋"的目标更宏大。 正如自然语言由字母和标点组成，构成细胞、骨骼和肌肉的蛋白质，是由一串串氨基酸组成。生物学家 发现，大型语言模型同样可用来识别氨基酸链中的潜在规律。 美国Dyno医药公司首席执行官埃里克·凯尔西克坦言："我曾认为蛋白质复杂到无法理解。但数据中自藏 秩序，譬如哪些氨基酸可置于衣壳的特定位置。现在，我们可利用AI自动分析数据，发现人类难以发 现的规律。"该公司正利用AI设计病毒衣壳，以实现更安全、高效的基因疗法。 AI的高 ...

Core Viewpoint - The article announces the recruitment of postdoctoral researchers and PhD students by Dr. Ronghui Li's research group at the National University of Singapore, focusing on somatic reprogramming and stem cell development for drug screening and regenerative medicine [2][4]. Group 1: Research Focus - The main research directions include the simulation of organoid or embryonic development using stem cells to produce functional tissues or cells [3] - Editing and precise regulation of multicellular organoid or embryonic systems [3] - Cell reprogramming to restore and enhance engineered cell functions for improved therapeutic applications [3] Group 2: Recruitment Details - The group is open to recruiting postdoctoral researchers, PhD students, and outstanding undergraduate or intern candidates, including those funded by CSC [4] - Interested candidates are encouraged to send their resumes to the provided email address, with specific subject line instructions [4] - The article also mentions the establishment of professional communication groups to facilitate research dissemination and collaboration [7]